Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.52 |
| ▸ | NAMPT | P43490 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14307160 | 0.93 | GSK3B (0.51) | GSK3BNAMPTKMT2ACHEK1CYP2C9 | |
| SCHEMBL13120522 | 0.91 | GSK3B (0.65) | GSK3B | |
| SCHEMBL14607249 | 0.91 | GSK3B (0.55) | GSK3BNAMPTCHEK1CYP2C9LMNA | |
| SCHEMBL14418840 | 0.90 | GSK3B (0.53) | GSK3BNAMPTCHEK1CYP2C9LMNA | |
| SCHEMBL12954082 | 0.90 | GSK3B (0.53) | GSK3BNAMPTKMT2ACHEK1CYP2C9 | |
| SCHEMBL12954475 | 0.90 | GSK3B (0.58) | GSK3BNAMPTCHEK1CYP2C9LMNA | |
| SCHEMBL13289097 | 0.89 | GSK3B (0.59) | GSK3BNAMPTCHEK1LMNA | |
| SCHEMBL14545841 | 0.88 | GSK3B (0.56) | GSK3BNAMPTKMT2ACHEK1CYP2C9 | |
| SCHEMBL13289015 | 0.88 | GSK3B (0.54) | GSK3BNAMPTCHEK1CYP2C9 | |
| SCHEMBL13288870 | 0.88 | GSK3B (0.56) | GSK3BNAMPTCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885NAMPT 579/4885KMT2A 1221/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885NAMPT 579/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.